[{"NetIncomeLoss_1_Q3_USD":-84660000.0,"AccruedRoyaltiesCurrent_0_Q3_USD":2438000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":156683000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":158129000.0,"CommitmentsAndContingencies_0_Q3_USD":null,"AccruedLiabilitiesCurrent_0_Q3_USD":88385000.0,"InventoryFinishedGoodsNetOfReserves_0_Q3_USD":1851000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":509000.0,"EquitySecuritiesFvNiCost_0_Q3_USD":191589000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":309467000.0,"Depreciation_3_Q3_USD":986000.0,"IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_3_Q3_USD":-653000.0,"InterestIncomeExpenseNonoperatingNet_3_Q3_USD":6056000.0,"InterestIncomeExpenseNonoperatingNet_1_Q3_USD":1242000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q3_USD":6485000.0,"AssetsCurrent_0_Q3_USD":730213000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":267909000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":81592000.0,"CostOfGoodsAndServicesSold_3_Q3_USD":7703000.0,"CostOfGoodsAndServicesSold_1_Q3_USD":2005000.0,"PaymentsToAcquireAvailableForSaleSecurities_3_Q3_USD":100808000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":19704000.0,"ResearchAndDevelopmentInProcess_3_Q3_USD":44280000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q3_USD":7043000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3_Q3_USD":415863000.0,"EquitySecuritiesFvNi_0_Q3_USD":192089000.0,"CommonStockSharesIssued_0_Q3_shares":158863541.0,"InventoryWorkInProcessNetOfReserves_0_Q3_USD":4045000.0,"StockIssuedDuringPeriodValueIssuedForServices_3_Q3_USD":44280000.0,"Assets_0_Q3_USD":795664000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":212000.0,"OperatingLeaseLiability_0_Q3_USD":49200000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":216000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":257014000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":120083000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":61338000.0,"IncreaseDecreaseInPrepaidExpense_3_Q3_USD":11403000.0,"PrepaidExpenseCurrent_0_Q3_USD":30009000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":17853000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":-1262000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":-202000.0,"AccountsReceivableNetCurrent_0_Q3_USD":46344000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":194000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":-199000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_0_Q3_USD":1100000.0,"CommonStockValue_0_Q3_USD":16000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0_Q3_Security":1.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":62870000.0,"CostsAndExpenses_3_Q3_USD":540172000.0,"CostsAndExpenses_1_Q3_USD":206476000.0,"IncreaseDecreaseInInventories_3_Q3_USD":1671000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-214612000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-85631000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-3751000.0,"AmortizationOfIntangibleAssets_3_Q3_USD":1108000.0,"AmortizationOfIntangibleAssets_1_Q3_USD":400000.0,"OtherAssetsNoncurrent_0_Q3_USD":1545000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":452352000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":45343000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":2573288000.0,"Liabilities_0_Q3_USD":140797000.0,"GainLossOnInvestments_3_Q3_USD":-1262000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-967000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-971000.0,"ShareBasedCompensation_3_Q3_USD":63227000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":48232000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":263655000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":10563000.0,"CommonStockSharesOutstanding_0_Q3_shares":158863541.0,"NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_3_Q3_USD":926000.0,"RestrictedCashNoncurrent_0_Q3_USD":5770000.0,"InvestmentsFairValueDisclosure_0_Q3_USD":632160000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_0_Q3_USD":4001000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-214630000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-84859000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3_Q3_USD":-4000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q3_USD":-4000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-108678000.0,"InventoryRawMaterialsNetOfReserves_0_Q3_USD":2083000.0,"GainLossOnDispositionOfAssets_3_Q3_USD":-281000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q3_USD":5134000.0,"LiabilitiesCurrent_0_Q3_USD":91856000.0,"AccountsPayableCurrent_0_Q3_USD":3471000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_Q3_USD":-4000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":3340000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q3_USD":1477000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q3_pure":0.047,"IncreaseDecreaseInOtherOperatingAssets_3_Q3_USD":-50000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_0_Q3_USD":4001000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":458122000.0,"OperatingLeasePayments_3_Q3_USD":3710000.0,"OperatingLeasePayments_1_Q3_USD":1128000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":8427000.0,"NetIncomeLoss_3_Q3_USD":-214824000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-1918946000.0,"IncreaseDecreaseInOtherOperatingLiabilities_3_Q3_USD":737000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_3_Q3_USD":-821000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":5588000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":62870000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"InterestReceivableCurrent_0_Q3_USD":1440000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q3_USD":12138000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q3_USD":6260000.0,"CommonStockSharesAuthorized_0_Q3_shares":225000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":320748000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":120577000.0,"OperatingIncomeLoss_3_Q3_USD":-219424000.0,"OperatingIncomeLoss_1_Q3_USD":-85899000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":192089000.0,"InventoryNet_0_Q3_USD":7979000.0,"PreferredStockValue_0_Q3_USD":null,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":732000.0,"OperatingLeaseCost_3_Q3_USD":4750000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":795664000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":24197000.0,"PreferredStockSharesAuthorized_0_Q3_shares":5000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":63227000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":21372000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":3857000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q3_USD":400000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3_Q3_USD":41571000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q3_USD":41190000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.37,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.54,"ProfitLoss_3_Q3_USD":-214824000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":3598000.0,"StockholdersEquity_0_Q3_USD":654867000.0,"OperatingLeaseCost_1_Q3_USD":1835000.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":18537000.0,"Ticker":"ACAD","CIK":"1070494","name":"ACADIA PHARMACEUTICALS INC","OfficialName":"ACADIA Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3501345407.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201104"}]